Fig. 7

Analysis of chemotherapeutic drug sensitivity in relation to USP39 expression in pancreatic adenocarcinoma (PAAD). (A) Pan-cancer correlation analysis between USP39 expression and drug sensitivity profiles from the GDSC database. (B-M) Comparative analysis of drug sensitivity between USP39 high- and low-expression groups in PAAD patients for multiple therapeutic agents: bleomycin, doxorubicin, embelin, gemcitabine, axitinib, bosutinib, camptothecin, dimethyloxallyl glycine, gefitinib, metformin, sunitinib, and temsirolimus